HBM Holdings Limited has issued a positive profit alert, indicating an expected profit for the six months ending June 30, 2025, ranging from approximately US$68 million to US$74 million. This anticipated increase in profit is primarily attributed to ongoing strategic partnerships with global pharmaceutical companies, including a significant collaboration with AstraZeneca PLC. The forecast is based on a preliminary assessment of the Group's unaudited management accounts for the Reporting Period. Shareholders and potential investors are advised to exercise caution and seek professional advice when dealing in the company's securities, as the actual results may differ from this preliminary assessment. The official interim results announcement is expected to be published by the end of August 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.